The estimated Net Worth of Amro A. Albanna is at least $1.68 Million dollars as of 19 July 2022. Mr. Albanna owns over 1 units of ADiTx Therapeutics stock worth over $0 and over the last 4 years he sold ADTX stock worth over $0. In addition, he makes $1,678,060 as Chairman of the Board, President, and Chief Executive Officer at ADiTx Therapeutics.
Amro has made over 2 trades of the ADiTx Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 1 units of ADTX stock worth $20,000 on 19 July 2022.
The largest trade he's ever made was buying 3,400 units of ADiTx Therapeutics stock on 1 June 2021 worth over $9,962. On average, Amro trades about 486 units every 59 days since 2020. As of 19 July 2022 he still owns at least 1 units of ADiTx Therapeutics stock.
You can see the complete history of Mr. Albanna stock trades at the bottom of the page.
Amro A. Albanna serves as Chairman of the Board, President, Chief Executive Officer of the Company. In 2010, Mr. Albanna co-founded Innovation Economy Corporation (“IEC”), formed to license and commercialize innovations and create a group of life and health subsidiaries. From 2010 until 2017, Mr. Albanna was Chief Executive Officer and a Director of IEC and Olfactor Laboratories, Inc., a majority-owned subsidiary of IEC. From 2010 to August 2016, he was the Chief Executive Officer and a Director of Nano Engineered Applications, Inc., another majority-owned subsidiary of IEC. In 2003, Mr. Albanna founded Qmotions, Inc. (subsequently renamed Deal A Day Group Corp.). He served as its Chief Executive Officer and a Director until 2011. Qmotions used 3-D spatial tracking and pattern recognition technologies to develop motion-capturing video game controllers. In 2002, Mr. Albanna was a co-founder of Digital Angel Corporation – a company formed via the merger of three private companies (one being TTC below) into a fourth publicly traded company (American Stock Exchange) and was placed in charge of commercializing its GPS/wireless technologies. Around that time, Mr. Albanna co-founded an incubator for startups at the University of California, Riverside Research Park which was acquired in 2007. In 1997, he founded Timely Technology Corporation (“TTC”), which designed and developed e-commerce software for education, retail and finance. TTC was acquired in 2000 by a Nasdaq-listed company. Mr. Albanna graduated from California State University San Bernardino in 1991 with a B.S. in Business Administration with concentration in Computer Information Systems. He completed graduate coursework in Computer Science and Engineering at California State University, Long Beach from 1992 to 1993. In 2019, Mr. Albanna completed coursework in Immunology and Genetics at Harvard Medical School HMX online learning platform. Albanna’s expertise leading technology companies across various sectors, leading private and
As the Chairman of the Board, President, and Chief Executive Officer of ADiTx Therapeutics, the total compensation of Amro Albanna at ADiTx Therapeutics is $1,678,060. There are no executives at ADiTx Therapeutics getting paid more.
Amro Albanna is 50, he's been the Chairman of the Board, President, and Chief Executive Officer of ADiTx Therapeutics since 2017. There are 10 older and 2 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.
Amro's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.
Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin, and Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
ADiTx Therapeutics executives and other stock owners filed with the SEC include: